This paper was compiled to give guidance on the assessment, evaluation and control of occupational exposure to inhalable lithium and its hydride and hydroxide compounds, with an emphasis on recommending a health-based guidance occupational exposure value.
While there is a lot of data on the effects of lithium compounds administered as medication for psychiatric illnesses, there is little published quantitative dose response/risk epidemiology for the occupational use of lithium and its compounds. However, international studies have shown that systemic adverse effects due to lithium (e.g. increased urination, shakiness of the hands, increased thirst), as sometimes seen when used therapeutically to treat psychiatric illnesses, are unlikely to occur at the lower exposure levels of lithium and lithium compounds in the workplace.
Published September 2018